Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Colorcon
Fish and Richardson
Mallinckrodt
Cerilliant
Citi
McKesson
Cantor Fitzgerald
Harvard Business School

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022081

« Back to Dashboard

NDA 022081 describes LETAIRIS, which is a drug marketed by Gilead and is included in one NDA. It is available from one supplier. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the LETAIRIS profile page.

The generic ingredient in LETAIRIS is ambrisentan. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ambrisentan profile page.
Summary for 022081
Tradename:LETAIRIS
Applicant:Gilead
Ingredient:ambrisentan
Patents:4
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 022081
Suppliers and Packaging for NDA: 022081
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LETAIRIS ambrisentan TABLET;ORAL 022081 NDA Gilead Sciences, Inc 61958-0801 N 61958-0801-1
LETAIRIS ambrisentan TABLET;ORAL 022081 NDA Gilead Sciences, Inc 61958-0801 N 61958-0801-2

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Jun 15, 2007TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 2, 2018
Regulatory Exclusivity Use:REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY
Patent:➤ Sign UpPatent Expiration:Dec 11, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL
Patent:➤ Sign UpPatent Expiration:Dec 11, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL

Expired US Patents for NDA 022081

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead LETAIRIS ambrisentan TABLET;ORAL 022081-002 Jun 15, 2007 ➤ Sign Up ➤ Sign Up
Gilead LETAIRIS ambrisentan TABLET;ORAL 022081-001 Jun 15, 2007 ➤ Sign Up ➤ Sign Up
Gilead LETAIRIS ambrisentan TABLET;ORAL 022081-001 Jun 15, 2007 ➤ Sign Up ➤ Sign Up
Gilead LETAIRIS ambrisentan TABLET;ORAL 022081-001 Jun 15, 2007 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Moodys
UBS
Fuji
Fish and Richardson
Teva
McKesson
Chinese Patent Office
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.